SLC5A2 and type 2 diabetes mellitus: This combined approach offers a robust foundation for evaluating the cardiovascular impact of SGLT-2 inhibitors. The RCT component of our analysis focuses on the cardiovascular effects of various SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin) in T2DM patients.